Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA)

**

· *Morgan Stanley raised its Moderna price target to $90 from $37, citing "initial promising Covid-19 vaccine data," according to a Wednesday note.  *
· *That's a 26% jump from where shares of Moderna currently trade. *
· *The bank risk-adjusted its estimates following the early results of the vaccine and now sees a...